

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Aug-2023  
Document Type: USP Monographs  
DocId: GUID-55284122-5DFA-4149-B29A-2E8EC1BFC2B0\_5\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M61390\\_05\\_01](https://doi.org/10.31003/USPNF_M61390_05_01)  
DOI Ref: xfs22

© 2025 USPC  
Do not distribute

## Penicillamine Capsules

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click [www.uspnf.com/rb-penicillamine-caps-20230728](http://www.uspnf.com/rb-penicillamine-caps-20230728).

### DEFINITION

Penicillamine Capsules contain NLT 90.0% and NMT 110.0% of the labeled amount of penicillamine ( $C_5H_{11}NO_2S$ ).

### IDENTIFICATION

#### • A. THIN-LAYER CHROMATOGRAPHY

**Standard solution:** 100 mg of [USP Penicillamine RS](#) in 10 mL of [methanol](#). Add 2 drops of [3 N hydrochloric acid](#) and mix.

**Sample solution:** Transfer a portion of Capsule contents, containing nominally about 100 mg of penicillamine, to a 10-mL volumetric flask, and dilute with [methanol](#) to volume. Add 2 drops of [3 N hydrochloric acid](#), mix, and filter. Use the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), General Procedures, Thin-Layer Chromatography](#).)

**Mode:** TLC

**Adsorbent:** 0.25-mm layer of chromatographic silica gel mixture, heated at 105° for 30 min, and allowed to cool before use

**Application volume:** 10  $\mu$ L

**Developing solvent system:** [Butyl alcohol](#), [glacial acetic acid](#), and [water](#) (8:2:2)

**Spray reagent:** 3-mg/mL solution of [ninhydrin](#) in [dehydrated alcohol](#)

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Separately apply the *Sample solution* and the *Standard solution* to the plate. Develop the chromatogram in the *Developing solvent system* until the solvent front has moved three-fourths the length of the plate. Remove the plate, mark the solvent front, allow the solvent to evaporate, and place the plate in an atmosphere of iodine vapors. After a few minutes, spray the plate with *Spray reagent*, heat it at 105° for 10 min, allow it to cool, and examine it.

**Acceptance criteria:** The  $R_F$  values, colors, and intensities of the principal spots from the *Sample solution* correspond to those from the *Standard solution*.

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Mobile phase:** 6.9 g/L of [monobasic sodium phosphate](#) and 0.2 g/L of [sodium 1-hexanesulfonate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of  $3.0 \pm 0.1$ .

**Diluent:** 1.0 g/L of [edetate disodium](#) in [water](#)

**System suitability solution:** 1 mg/mL of [USP Penicillamine RS](#) and 0.1 mg/mL of [USP Penicillamine Disulfide RS](#) in *Diluent*

**Standard solution:** 1.25 mg/mL of [USP Penicillamine RS](#) in *Diluent*

**Sample solution:** Nominally equivalent to 1.25 mg/mL of penicillamine in *Diluent* prepared as follows. Transfer the contents of Capsules (NLT 10) to a suitable volumetric flask. Add the empty Capsule shells to the flask, and add sufficient *Diluent* to the flask to fill it to three-fourths of its capacity. Shake for 1 min, and allow the mixture to stand for 90 min. Dilute with *Diluent* to volume. Pass a portion of this solution through a suitable filter of 1- $\mu$ m or finer pore size, and use the clear filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 210 nm

**Column:** 3.9-mm  $\times$  30-cm; 10- $\mu$ m packing [L1](#)

**Flow rate:** 1.6 mL/min

**Injection volume:** 20 µL

### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for penicillamine and penicillamine disulfide are 0.7 and 1.0, respectively.]

### Suitability requirements

**Resolution:** NLT 3.0 between penicillamine and penicillamine disulfide, *System suitability solution*

**Relative standard deviation:** NMT 1.0%, *Standard solution*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of penicillamine (C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>S) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of penicillamine from the *Sample solution*

$r_S$  = peak response of penicillamine from the *Standard solution*

$C_S$  = concentration of [USP Penicillamine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of penicillamine in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

### PERFORMANCE TESTS

**Change to read:**

- [DISSOLUTION \(711\)](#).

#### ▲ Test 1 ▲ (RB 1-Aug-2023)

**Medium:** 0.1 N [hydrochloric acid](#); 900 mL

**Apparatus 1:** 100 rpm

**Time:** 30 min

#### Procedure for a pooled sample

**Dilute hydrochloric acid:** Dilute 37 mL of [hydrochloric acid](#) with [water](#) to 1 L.

**Dilute sulfuric acid:** Dilute 1 mL of [sulfuric acid](#) with [water](#) to 50 mL.

**Ammonium sulfamate reagent:** 2.5 mg/mL of [ammonium sulfamate](#) in *Dilute hydrochloric acid*

**N-(1-Naphthyl)ethylenediamine dihydrochloride reagent:** 1 mg/mL of [N-\(1-naphthyl\)ethylenediamine dihydrochloride](#) in *Dilute hydrochloric acid*

**Sulfanilamide–mercuric chloride reagent:** 1 mg/mL of [sulfanilamide](#) and 1 mg/mL of [mercuric chloride](#) in *Dilute hydrochloric acid*

**Sodium nitrite reagent:** 2 mg/mL of [sodium nitrite](#) in *Dilute sulfuric acid*. Prepare fresh.

**Standard solution:** 250 µg/mL of [USP Penicillamine RS](#) in 0.1 N [hydrochloric acid](#)

**Sample solution:** Withdraw a portion of the solution under test, containing nominally about 278 µg of penicillamine, and pass through a suitable filter.

**Blank:** Volume of 0.1 N hydrochloric acid equivalent to a volume of the *Sample solution*

#### Instrumental conditions

**Mode:** UV-Vis

**Analytical wavelength:** 540 nm

**Cell:** 1 cm

**Analysis:** Pipet the *Sample solution* into a 100-mL volumetric flask. Into a similar flask, transfer the reagent *Blank*, and into a third 100-mL volumetric flask, pipet 1 mL of *Standard solution*. Treat each flask as follows. Add by pipet 3 mL of *Sodium nitrite reagent*, and mix by swirling occasionally. After 5 min, add 10 mL of *Ammonium sulfamate reagent*, swirl, and allow to stand for an additional 5 min. Add 5 mL of *Sulfanilamide–mercuric chloride reagent*, swirl, and immediately add 10 mL of *N-(1-Naphthyl)ethylenediamine dihydrochloride reagent*. Dilute with water to volume and mix. Determine the absorbances of both solutions against the *Blank*.

Calculate the percentage of the labeled amount of penicillamine (C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>S) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times V \times (1/L) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_s$  = absorbance of the *Standard solution*

$C_s$  = concentration of [USP Penicillamine RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of the Medium, 900 mL

$L$  = label claim (mg/Capsule)

**Tolerances:** NLT 80% ( $Q$ ) of the labeled amount of penicillamine ( $C_5H_{11}NO_2S$ ) is dissolved.

#### Procedure for a unit sample

**Buffer solution:** 50 mM solution of [monobasic potassium phosphate](#) buffer at a pH of 3.0

**Mobile phase:** [Methanol](#) and *Buffer solution* (3:97)

**Sample solution:** Proceed as directed in [Dissolution \(711\), Procedure](#). After 30 min, withdraw 10 mL of solution from each vessel, and immediately pass each aliquot through a polyvinylidene difluoride filter of 0.45- $\mu$ m pore size. Discard the first 2 mL of filtered solution, and chromatograph the remaining filtrate.

**System suitability solution:** [USP Penicillamine RS](#) at a concentration similar to the *Sample solution* and 0.002 mg/mL of [USP Penicillamine Disulfide RS](#) in 0.1 N [hydrochloric acid](#)

**Standard solution:** [USP Penicillamine RS](#) in 0.1 N [hydrochloric acid](#) at a concentration similar to the *Sample solution*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 210 nm

**Column:** 4.6-mm  $\times$  15-cm; 5- $\mu$ m packing [L1](#)

**Flow rate:** 1.0 mL/min

**Injection volume:** 30  $\mu$ L

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

#### Suitability requirements

**Resolution:** NLT 2.0 between penicillamine and penicillamine disulfide, *System suitability solution*

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Sample solution* and *Standard solution*

Calculate the percentage of penicillamine ( $C_5H_{11}NO_2S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_s \times V \times (1/L) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Penicillamine RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of Medium, 900 mL

$L$  = label claim (mg/Capsule)

**Tolerances:** NLT 80% ( $Q$ ) of the labeled amount of penicillamine ( $C_5H_{11}NO_2S$ ) is dissolved.

**▲Test 2:** If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 2*.

**Medium:** 0.1 N [hydrochloric acid](#); 500 mL

**Apparatus 1:** 100 rpm

**Time:** 30 min

**Solution A:** Transfer 10 mL of [phosphoric acid](#) to a 100-mL volumetric flask, and dilute with [water](#) to volume.

**Buffer:** Dissolve 6.8 g of [potassium phosphate, monobasic](#) in 1 L of [water](#). Adjust with *Solution A* to a pH of 3.0.

**Mobile phase:** [Methanol](#) and *Buffer* (3:97)

**Impurity stock solution:** 0.1 mg/mL of [USP Penicillamine Disulfide RS](#) in *Medium*. Sonicate to dissolve.

**System suitability solution:** 0.5 mg/mL of [USP Penicillamine RS](#) and 0.01 mg/mL of [USP Penicillamine Disulfide RS](#) prepared as follows.

Transfer an appropriate quantity of [USP Penicillamine RS](#) to a suitable volumetric flask. Add 10% of the flask volume of *Impurity stock solution*. Dilute with *Medium* to volume.

**Standard solution:** 0.5 mg/mL of [USP Penicillamine RS](#) in *Medium*. Sonicate to dissolve.

**Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45-μm pore size.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 210 nm

**Column:** 4.6-mm × 15-cm; 3-μm packing [L1](#)

**Flow rate:** 1 mL/min

**Injection volume:** 10 μL

**Column temperature:** 30°

**Run time:** NLT 3 times the retention time of penicillamine

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for penicillamine and penicillamine disulfide are about 1.0 and 1.1, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between penicillamine and penicillamine disulfide, *System suitability solution*

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of penicillamine ( $C_5H_{11}NO_2S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response of penicillamine from the *Sample solution*

$r_S$  = peak response of penicillamine from the *Standard solution*

$C_S$  = concentration of [USP Penicillamine RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of *Medium*, 500 mL

$L$  = label claim (mg/Capsule)

**Tolerances:** NLT 80% (Q) of the labeled amount of penicillamine ( $C_5H_{11}NO_2S$ ) is dissolved. ▲ (RB 1-Aug-2023)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

#### IMPURITIES

##### • LIMIT OF PENICILLAMINE DISULFIDE

**Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.

**Standard solution:** 0.025 mg/mL of [USP Penicillamine Disulfide RS](#) in *Diluent*

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for penicillamine and penicillamine disulfide are 0.7 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 3.0 between penicillamine and penicillamine disulfide, *System suitability solution*

**Relative standard deviation:** NMT 2.0% for penicillamine disulfide, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of penicillamine disulfide ( $C_{10}H_{20}N_2O_4S_2$ ) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak area of penicillamine disulfide from the *Sample solution*

$r_S$  = peak area of penicillamine disulfide from the *Standard solution*

$C_S$  = concentration of [USP Penicillamine Disulfide RS](#) in the *Standard solution* (mg/mL)

Acceptance criteria: NMT 2.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.

Add the following:


- ▲ • **LABELING:** When more than one dissolution test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.▲ (RB 1-Aug-2023)

- **USP REFERENCE STANDARDS** (11).

USP Penicillamine RS

USP Penicillamine Disulfide RS

3,3'-Dithiodi-D-valine.



Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question             | Contact   | Expert Committee          |
|----------------------------|---|---------------------------|
| PENICILLAMINE CAPSULES     | <a href="#">Documentary Standards Support</a>                               | SM12020 Small Molecules 1 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM12020 Small Molecules 1 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(3)

Current DocID: GUID-55284122-5DFA-4149-B29A-2E8EC1BFC2B0\_5\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M61390\\_05\\_01](https://doi.org/10.31003/USPNF_M61390_05_01)

DOI ref: [xfs22](#)